For individuals battling Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a serious condition, the arrival of Tafamidis and Attruby represents a significant change. These innovative therapies protect the transthyretin protein, slowing its harmful build-up and alleviating the impact of the condition . Individuals are now reporting benefits in their h